Review



ic 50 calculation with graphpad prism 7 software  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc ic 50 calculation with graphpad prism 7 software
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Calculation With Graphpad Prism 7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ic+50+calculation+with+graphpad+prism+7+software/ic50+values/pmc11697375-239-3-8
    Average 90 stars, based on 1 article reviews
    ic 50 calculation with graphpad prism 7 software - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan"

    Article Title: A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan

    Journal: Scientific Reports

    doi: 10.1038/s41598-024-84566-y

    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Figure Legend Snippet: Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.

    Techniques Used: Control, CCK-8 Assay

    Related Articles

    Software:

    Article Title: A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan
    Article Snippet: Absorbance at 450 nm was measured using an iMark microplate reader and cell viability relative to that of PBS-treated control cells was calculated. .. IC 50 of sacituzumab govitecan was calculated with GraphPad Prism 7 software (GraphPad Software, San Diego, CA). ..



    Similar Products

    ic 50 calculation with graphpad prism 7 software  (GraphPad Software Inc)
    90
    GraphPad Software Inc ic 50 calculation with graphpad prism 7 software
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Calculation With Graphpad Prism 7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ic+50+calculation+with+graphpad+prism+7+software/ic50+values/pmc11697375-239-3-8
    Average 90 stars, based on 1 article reviews
    ic 50 calculation with graphpad prism 7 software - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.

    Journal: Scientific Reports

    Article Title: A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan

    doi: 10.1038/s41598-024-84566-y

    Figure Lengend Snippet: Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.

    Article Snippet: IC 50 of sacituzumab govitecan was calculated with GraphPad Prism 7 software (GraphPad Software, San Diego, CA).

    Techniques: Control, CCK-8 Assay